Back to Journals » OncoTargets and Therapy » Volume 6

Survivin – biology and potential as a therapeutic target in oncology

Authors Cheung CHA, Huang C, Tsai F, Lee JY, Cheng SM, Chang Y, Huang Y, Chen S, Chang J

Received 30 June 2013

Accepted for publication 20 August 2013

Published 16 October 2013 Volume 2013:6 Pages 1453—1462

DOI https://doi.org/10.2147/OTT.S33374

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 6


Chun Hei Antonio Cheung,1,2 Chien-Chang Huang,3 Fang-Ying Tsai,4 Jane Ying-Chieh Lee,1 Siao Muk Cheng,2 Yung-Chieh Chang,1 Yi-Chun Huang,1 Shang-Hung Chen,5 Jang-Yang Chang3,6

1Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, 2Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, 3National Institute of Cancer Research, National Health Research Institutes, Tainan, 4South East Asian Health Education Center in Taiwan (SEAHECT), College of Medicine, National Cheng Kung University, Tainan, 5Division of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan, 6Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, Republic of China

Abstract: Survivin is a member of the inhibitor-of-apoptosis proteins (IAPs) family; its overexpression has been widely demonstrated to occur in various types of cancer. Overexpression of survivin also correlates with tumor progression and induces anticancer drug resistance. Interestingly, recent studies reveal that survivin exhibits multiple pro-mitotic and anti-apoptotic functions; the differential functions of survivin seem to be caused by differential subcellular localization, phosphorylation, and acetylation of this molecule. In this review, the complex expression regulations and post-translational modifications of survivin are discussed. This review also discusses how recent discoveries improve our understanding of survivin biology and also create opportunities for developing differential-functioned survivin-targeted therapy. Databases such as PubMed, Scopus® (Elsevier, New York, NY, USA), and SciFinder® (CAS, Columbus, OH, USA) were used to search for literature in the preparation of this review.

Keywords: survivin, BIRC5, IAP, XIAP, caspase-9, Samc, DIABLO

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]